"Caseness" for depression and anxiety in a depressed outpatient population: Symptomatic outcome as a function of baseline diagnostic categories

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 6, 2009, Pages 307-315

  Demyttenaere, Koen ^a   Verhaeghen, Anne ^a   Dantchev, Nicolas ^b   Grassi, Luigi ^c   Montejo, Angel L ^d   Perahia, David G S ^e,f   Quail, Deborah ^e   Reed, Catherine ^e   Tylee, Andre ^g   Bauer, Michael ^h  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF FERRARA   (Italy)

^d HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^e ELI LILLY AND COMPANY   (United States)

^f Gordon Hospital   (United Kingdom)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; MIXED ANXIETY AND DEPRESSION; OUTPATIENT CARE; PAIN ASSESSMENT; PSYCHOLOGIC ASSESSMENT; REMISSION; SELF CONCEPT; SHORT FORM 36; SOCIAL STATUS; SOMATOFORM DISORDER;

EID: 77957651971     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08m00748blu     Document Type: Article

References (36)

1. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of epidemiology of mental disorders (ESEMeD). J Affect Disord. 2008;110(1-2):84-93.
2. Linden M, Lecrubier Y, Bellantuono C, et al. The prescription of psychotropic drugs by primary care physicians: an international collaborative study. J Clin Psychopharmacol. 1999;19(2):132-140.
3. Yastrubetskaya O, Chiu E, O'Connel S. Is good clinical research practice for clinical trials good clinical practice? Int J Geriatr Psychiatry. 1997; 12(2):227-231.
4. Zimmerman M, Mattia JL, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry. 2002;159(3):469-473.
5. Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005; 162(7):1370-1372.
6. Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry. 2003;64(9):1091-1093.
7. Bauer M, Whybrow PC, Angst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry. 2002;3(2):69-86.
8. Cuijpers P, Smit F. Subthreshold depression as a risk indicator for major depressive disorder: a systematic review of prospective studies. Acta Psychiatr Scand. 2004;109(5):325-331.
9. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am. 2002;25(4):685-698.
10. Garcia-Cebrian A, Bauer M, Montejo AL, et al. Factors Influencing Depression Endpoints Research (FINDER): study design and population characteristics. Eur Psychiatry. 2008;23(1):57-65.
11. Bauer M, Monz BU, Montejo AL, et al. Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry. 2008;23(1):66-73.
12. Reed C, Monz BU, Perahia DG, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009;113(3):296-302.
13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67(6):361-370.
14. Barsky AJ, Wushak G, Klerman GL. Hypochondriasis: an evolution of the DSM-III criteria in medical outpatients. Arch Gen Psychiatry. 1986; 43(5):493-500.
15. Barsky AJ, Wushak G, Klerman GL. Psychiatric comorbidity in DSM-III-R hypochondriasis. Arch Gen Psychiatry. 1992;49(2):101-108.
16. Kelly AM. The minimum clinically significant difference in visual analogue scale pain does not differ with severity of pain. Emerg Med J. 2001;18(3):205-207.
17. Collins SL, Moore RA, McQuay HJ. The visual analogue pain intensity scale: what is moderate pain in millimetres? Pain. 1997;72(1-2):95-97.
18. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, Health Institute; 1993.
19. Ware JE, Kosinski M, Dewey JE, et al. How to Score Version 2 of the SF-36 Health Survey. Lincoln, RI: Quality Metric Incorporated; 2001.
20. Joukamaa M, Sohlman B, Lehtinen V. The prescription of psychotropic drugs in primary health care. Acta Psychiatr Scand. 1995;92(5): 359-364.
21. Mojtabai R. Datapoints: prescription patterns for mood and anxiety disorder in a community sample. Psychiatr Serv. 1999;50(12):1557.
22. Hunt C, Slade T, Andrews G. Generalized anxiety disorder and major depressive disorder comorbidity in the national survey of mental health and well-being. Depress Anxiety. 2004;20(1):23-31.
23. Carter RM, Wittchen HU, Pfister H, et al. One year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a national representative sample. Depress Anxiety. 2001;13(2):78-88.
24. Fava M, Rankin M, Wright E, et al. Anxiety disorders in major depression. Compr Psychiatry. 2000;41(2):97-102.
25. Rush AJ, Zimmerman M, Wisniewski SR, et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord. 2005;87(1):43-55.
26. Sartorius N, Ustun T, Costa e Silva J, et al. An international study of psychological problems in primary care: preliminary report from the World Health Organization collaborative project on psychological problems in general health care. Arch Gen Psychiatry. 1993;50(10):819-824.
27. McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with three pain conditions: results from a nationally representative sample. Pain. 2004;111(1-2):77-83.
28. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Comorbid painful physical symptoms and depression: prevalence, work loss and help seeking. J Affect Disord. 2006;92(2-3):185-193.
29. Demyttenaere K, Bonnewyn A, Bruffaerts R, et al. Comorbid painful physical symptoms and anxiety: prevalence, work-loss and help seeking. J Affect Disord. 2008;109(3):264-272.
30. Vaccarino AL, Sills TL, Evans KR, et al. Prevalence and association of somatic symptoms in patients with major depressive disorder. J Affect Disord. 2008;110(3):270-276.
31. Boulanger JP, Fournier M, Rosales D, et al. Mixed anxiety and depression: from theory to practice. J Clin Psychiatry. 1997;57(suppl 8):27-34.
32. Judd LL, Kessler RC, Paulus MP, et al. Comorbidity as a fundamental feature of generalized anxiety disorders: results from the National Comorbidity Study (NCS). Acta Psychiatr Scand. 1998;98(suppl 393):6-11.
33. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol. 2000;20(6):645-652.
34. Nelson JC. Anxious depression and response to treatment. Am J Psychiatry. 2008;165(3):297-299.
35. Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342-351.
36. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.